Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Biotech M&A is picking back up according to BiopharmaDive

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 15, 2023 11:30am

192 Views

Post# 35684289

RE:RE:RE:Biotech M&A is picking back up according to BiopharmaDive

Pharmaceutical Executive: October 2023, Volume 44, Issue 10
Published on: October 13, 2023
Management will be heavily focused on acquisitions where there are compelling strategic rationales and where the same results cannot be obtained internally or through licensing and strategic partnerships and geopolitical issues will not have a dramatic effect on drug demand or Big Pharma strategies.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing